Abstract
Background Despite the growing number of genetic risk loci identified for substance use traits (SUTs), the impact of these loci on protein abundance and their potential as therapeutic targets are unknown.
Methods To address this, we performed a proteome-wide association study (PWAS) by integrating human brain proteomes from discovery (Banner; N = 152) and validation (ROSMAP; N = 376) datasets with genome-wide association study (GWAS) summary statistics for 4 SUTs. The sample comprised 4 GWAS of European-ancestry individuals for smoking initiation [Smk] (N = 1,232,091), alcohol use disorder [AUD] (N = 313,959), cannabis use disorder [CUD] (N = 384,032), and opioid use disorder [OUD] (N = 302,585). We conducted transcriptome-wide association studies (TWAS) with human brain transcriptomic data to examine the overlap of genetic effects at the proteomic and transcriptomic levels and tested significant genes for causality through Colocalization analysis.
Results Twenty-seven genes (Smk=21, AUD=3, CUD=2, OUD=1) were significantly associated with cis-regulated brain protein abundance. There was evidence for causality in 6 genes (Smk: NT5C2, GMPPB, NQO1, SRR, and ACTR1B; AUD: CTNND1), which act by regulating brain protein abundance. Cis-regulated transcript levels for 8 genes (Smk=6, CUD=1, OUD=1) were associated with SUTs, indicating that genetic loci could confer risk for these SUTs by modulating both gene expression and proteomic abundance.
Conclusions Functional studies of the high-confidence risk proteins (SRR for Smk and CTNND1 for AUD) identified here are needed to determine whether they are modifiable targets and useful in developing medications and biomarkers for these SUTs.
Competing Interest Statement
Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals and Enthion Pharmaceruticals, a consultant to Sobrera Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka, and is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists" filed January 24, 2018. The other authors have no disclosures to make.
Funding Statement
This study was supported by the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center and NIH grants DA046345, AA028292, and AA026364.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (IRB) of Central Veterans Affairs gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals and Enthion Pharmaceruticals, a consultant to Sobrera Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka, and is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists” filed January 24, 2018. The other authors have no disclosures to make.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
